Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4591 AL 4605

Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels

Kuruppu S, Rajapakse NW, Spicer AJ, Parkington HC, Smith AI.

J Alzheimers Dis. 2016 Oct 4;54(3):891-895. doi: 10.3233/JAD-160492.

Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years

McGeer PL, Rogers J, McGeer EG.

J Alzheimers Dis. 2016 Oct 4;54(3):853-857. doi: 10.3233/JAD-160488.

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease

Brody M, Liu E, Di J, Lu M, Margolin RA, Werth JL, Booth K, Shadman A, Brashear HR, Novak G.

J Alzheimers Dis. 2016 Oct 18;54(4):1509-1519. doi: 10.3233/JAD-160369.

Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies

Golde TE.

J Neurochem. 2016 Oct;139 Suppl 2(Suppl 2):224-236. doi: 10.1111/jnc.13583. Epub 2016 May 4.

Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease

Ruthirakuhan M, Herrmann N, Suridjan I, Abraham EH, Farber I, Lanctôt KL.

Expert Opin Pharmacother. 2016 Dec;17(18):2417-2429. doi: 10.1080/14656566.2016.1258060. Epub 2016 Nov 22.

Non human primate models for Alzheimer's disease-related research and drug discovery

Van Dam D, De Deyn PP.

Expert Opin Drug Discov. 2017 Feb;12(2):187-200. doi: 10.1080/17460441.2017.1271320. Epub 2016 Dec 25.

Vascular biomarkers to predict response to exercise in Alzheimer's disease: the study protocol

Li D, Thomas R, Tsai MY, Li L, Vock DM, Greimel S, Yu F.

BMJ Open. 2016 Dec 30;6(12):e011054. doi: 10.1136/bmjopen-2016-011054.

Donepezil improves gait performance in older adults with mild Alzheimer's disease: a phase II clinical trial

Montero-Odasso M, Muir-Hunter SW, Oteng-Amoako A, Gopaul K, Islam A, Borrie M, Wells J, Speechley M.

J Alzheimers Dis. 2015;43(1):193-9. doi: 10.3233/JAD-140759.

Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview

Heckman PR, Wouters C, Prickaerts J.

Curr Pharm Des. 2015;21(3):317-31. doi: 10.2174/1381612820666140826114601.

Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease

Lan YL, Zhao J, Li S.

J Alzheimers Dis. 2015;43(4):1137-48. doi: 10.3233/JAD-141875.

Potential therapeutic implications of gelsolin in Alzheimer's disease

Ji L, Zhao X, Hua Z.

J Alzheimers Dis. 2015;44(1):13-25. doi: 10.3233/JAD-141548.

Biometals and their therapeutic implications in Alzheimer's disease

Ayton S, Lei P, Bush AI.

Neurotherapeutics. 2015 Jan;12(1):109-20. doi: 10.1007/s13311-014-0312-z.

Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease

Guzior N, Wieckowska A, Panek D, Malawska B.

Curr Med Chem. 2015;22(3):373-404. doi: 10.2174/0929867321666141106122628.

Therapeutic Interventions for the Suppression of Alzheimer's Disease: Quest for a Remedy

Fazili NA, Naeem A, Ashraf GM, Hua GS, Kamal MA.

Curr Drug Metab. 2015;16(5):346-53. doi: 10.2174/1389200215999141125115749.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias